Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Sandborn et al. 2020. Gastroenterology


Janus kinases (JAKs) are a group of proteins involved in the activation of immune cells. These cells trigger an excessive inflammation in the intestine in inflammatory bowel diseases (IBDs) and thus, JAKs have become a main molecular target to combat these conditions. In the last years, chemical inhibitors of JAKs, such as tofacitinib, have entered the market and proven their efficacy but the lack of JAK specificity has lead to the appearance of adverse effects side effects.


Previous studies point out that tofacitinib makes its therapeutic action mainly through the inhibition of JAK1, opening the door to treatments for IBD that target only this protein. In this article, a new selective JAK1 inhibitor,  upadacitinib, is evaluated for its safety and efficacy in a randomized trial of patients with Crohn’s disease. In it, upadacitinib induced remission in a significant proportion of patients, standing as a promising therapy for this IBD and highlighting the relevance of JAK1 as a strategic target to fight IBD. To the publication>